Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient

Table 2 Results of phase 3, CANagliflozin treatment and trial analysis-metformin plus SUIphonylurea, n = 469[14]

Parameters	Canagliflozin 100 mg	Canagliflozin 300 mg	Placebo	Comments
A1c (%) week 26	-0.85	-1.06	-0.13	P < 0.001
A1c (%) week 52	-0.74	-0.96	-0.01	P < 0.001
% Patients with A1c < 7% week 26	43.2	56.6	18.0	P < 0.001
% Patients with A1c < 7% week 52	39.4	52.6	18.7	P < 0.001
FPG (mg/dL) week 26	-21.6	-34.2	-	P < 0.001
FPG (mg/dL) week 52	-28.8	-37.8	-	P < 0.001
Weight	-1.10	-1.7	-	P < 0.001
Change in systolic blood pressure (mmHg)	-2.20	-1.6	-	Non significant
Change in pulse (beats/min)	0.90	-1.2	-0.4	Non significant

A1c: Hemoglobin A1c; FPG: Fasting plasma glucose.